Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

AKBA – Akebia Therapeutics Inc.

Float Short %

9.8

Margin Of Safety %

Put/Call OI Ratio

0.19

EPS Next Q Diff

EPS Last/This Y

0.3

EPS This/Next Y

0.29

Price

3.19

Target Price

7.4

Analyst Recom

1

Performance Q

12.72

Relative Volume

0.7

Beta

1.04

Ticker: AKBA




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25AKBA3.550.160.0835707
2025-07-28AKBA3.60.160.1337877
2025-07-29AKBA3.510.160.0738259
2025-07-30AKBA3.660.160.0838367
2025-07-31AKBA3.690.160.0038804
2025-08-01AKBA3.710.150.0039420
2025-08-04AKBA3.760.150.0239958
2025-08-05AKBA3.710.150.0039985
2025-08-06AKBA3.790.150.2040368
2025-08-07AKBA2.990.150.0841246
2025-08-08AKBA3.410.150.2643359
2025-08-11AKBA3.350.160.1145722
2025-08-12AKBA3.320.160.0046023
2025-08-13AKBA3.30.160.0045916
2025-08-14AKBA3.30.160.3345949
2025-08-15AKBA3.230.160.1346311
2025-08-18AKBA3.120.200.1938572
2025-08-19AKBA3.040.200.0138939
2025-08-20AKBA3.120.200.5640200
2025-08-21AKBA3.180.190.0740143
2025-08-22AKBA3.190.190.0640762
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25AKBA3.5637.5- -0.06
2025-07-28AKBA3.5837.5- -0.06
2025-07-29AKBA3.5137.5- -0.06
2025-07-30AKBA3.6637.5- -0.06
2025-07-31AKBA3.6837.5- -0.06
2025-08-01AKBA3.7237.5- -0.06
2025-08-04AKBA3.7637.5- -0.06
2025-08-05AKBA3.7237.5- -0.06
2025-08-06AKBA3.7937.5- -0.06
2025-08-07AKBA3.0137.5- -0.06
2025-08-08AKBA3.4237.5- -0.06
2025-08-11AKBA3.3537.5- -0.06
2025-08-12AKBA3.3280.0- -0.03
2025-08-13AKBA3.3080.0- -0.03
2025-08-14AKBA3.3080.0- -0.03
2025-08-15AKBA3.2380.0- -0.03
2025-08-18AKBA3.1280.0- -0.03
2025-08-19AKBA3.0480.0- -0.03
2025-08-20AKBA3.1280.0- -0.03
2025-08-21AKBA3.1880.0- -0.03
2025-08-22AKBA3.1980.0- -0.03
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25AKBA-3.5449.4910.08
2025-07-28AKBA-3.5449.1810.08
2025-07-29AKBA-3.5449.1810.08
2025-07-30AKBA-3.5449.1810.08
2025-07-31AKBA-3.5449.1810.08
2025-08-01AKBA-3.5449.1810.08
2025-08-04AKBA-3.5435.5410.08
2025-08-05AKBA-1.1135.5410.08
2025-08-06AKBA-1.1135.5410.08
2025-08-07AKBA-1.1135.5410.08
2025-08-08AKBA-1.1135.5410.08
2025-08-11AKBA-1.1035.129.99
2025-08-12AKBA-1.1035.129.66
2025-08-13AKBA-1.1035.129.66
2025-08-14AKBA-1.1035.129.66
2025-08-15AKBA-1.1035.129.66
2025-08-18AKBA-1.1024.889.80
2025-08-19AKBA-0.8324.889.80
2025-08-20AKBA-0.8324.889.80
2025-08-21AKBA-0.8324.889.80
2025-08-22AKBA-0.8324.889.80
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.02

Avg. EPS Est. Next Quarter

-0.03

Insider Transactions

-0.83

Institutional Transactions

24.88

Beta

1.04

Average Sales Estimate Current Quarter

48

Average Sales Estimate Next Quarter

48

Fair Value

Quality Score

43

Growth Score

53

Sentiment Score

52

Actual DrawDown %

69.8

Max Drawdown 5-Year %

-97.6

Target Price

7.4

P/E

Forward P/E

41.97

PEG

P/S

4.15

P/B

28.71

P/Free Cash Flow

EPS

-0.17

Average EPS Est. Cur. Y​

-0.03

EPS Next Y. (Est.)

0.26

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-17.91

Relative Volume

0.7

Return on Equity vs Sector %

-149.5

Return on Equity vs Industry %

-132.7

EPS 1 7Days Diff

EPS 1 30Days Diff

0.03

EBIT Estimation

Akebia Therapeutics, Inc.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 181
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090 for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
stock quote shares AKBA – Akebia Therapeutics Inc. Stock Price stock today
news today AKBA – Akebia Therapeutics Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch AKBA – Akebia Therapeutics Inc. yahoo finance google finance
stock history AKBA – Akebia Therapeutics Inc. invest stock market
stock prices AKBA premarket after hours
ticker AKBA fair value insiders trading